389 related articles for article (PubMed ID: 24029229)
1. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.
Leung-Hagesteijn C; Erdmann N; Cheung G; Keats JJ; Stewart AK; Reece DE; Chung KC; Tiedemann RE
Cancer Cell; 2013 Sep; 24(3):289-304. PubMed ID: 24029229
[TBL] [Abstract][Full Text] [Related]
2. Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.
Mimura N; Fulciniti M; Gorgun G; Tai YT; Cirstea D; Santo L; Hu Y; Fabre C; Minami J; Ohguchi H; Kiziltepe T; Ikeda H; Kawano Y; French M; Blumenthal M; Tam V; Kertesz NL; Malyankar UM; Hokenson M; Pham T; Zeng Q; Patterson JB; Richardson PG; Munshi NC; Anderson KC
Blood; 2012 Jun; 119(24):5772-81. PubMed ID: 22538852
[TBL] [Abstract][Full Text] [Related]
3. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.
Ling SC; Lau EK; Al-Shabeeb A; Nikolic A; Catalano A; Iland H; Horvath N; Ho PJ; Harrison S; Fleming S; Joshua DE; Allen JD
Haematologica; 2012 Jan; 97(1):64-72. PubMed ID: 21993678
[TBL] [Abstract][Full Text] [Related]
4. Why proteasome inhibitors cannot ERADicate multiple myeloma.
Orlowski RZ
Cancer Cell; 2013 Sep; 24(3):275-7. PubMed ID: 24029222
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.
Obeng EA; Carlson LM; Gutman DM; Harrington WJ; Lee KP; Boise LH
Blood; 2006 Jun; 107(12):4907-16. PubMed ID: 16507771
[TBL] [Abstract][Full Text] [Related]
6. [Determinants of sensitivity to proteasome inhibitors and strategies to overcome acquired resistance to bortezomib in multiple myeloma].
Iida S; Ri M
Rinsho Ketsueki; 2014 Mar; 55(3):304-10. PubMed ID: 24681933
[No Abstract] [Full Text] [Related]
7. Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells.
Wada N; Kawano Y; Fujiwara S; Kikukawa Y; Okuno Y; Tasaki M; Ueda M; Ando Y; Yoshinaga K; Ri M; Iida S; Nakashima T; Shiotsu Y; Mitsuya H; Hata H
Int J Oncol; 2015 Mar; 46(3):963-72. PubMed ID: 25530098
[TBL] [Abstract][Full Text] [Related]
8. ATF6 upregulates XBP1S and inhibits ER stress-mediated apoptosis in osteoarthritis cartilage.
Guo FJ; Xiong Z; Lu X; Ye M; Han X; Jiang R
Cell Signal; 2014 Feb; 26(2):332-42. PubMed ID: 24269637
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
Tagoug I; Jordheim LP; Herveau S; Matera EL; Huber AL; Chettab K; Manié S; Dumontet C
Clin Cancer Res; 2013 Jul; 19(13):3556-66. PubMed ID: 23674497
[TBL] [Abstract][Full Text] [Related]
10. Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells.
Nishimura N; Radwan MO; Amano M; Endo S; Fujii E; Hayashi H; Ueno S; Ueno N; Tatetsu H; Hata H; Okamoto Y; Otsuka M; Mitsuya H; Matsuoka M; Okuno Y
Cancer Sci; 2019 Oct; 110(10):3275-3287. PubMed ID: 31368616
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells.
Lee AH; Iwakoshi NN; Anderson KC; Glimcher LH
Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9946-51. PubMed ID: 12902539
[TBL] [Abstract][Full Text] [Related]
12. Endoplasmic reticulum stress in malignancy.
Clarke HJ; Chambers JE; Liniker E; Marciniak SJ
Cancer Cell; 2014 May; 25(5):563-73. PubMed ID: 24823636
[TBL] [Abstract][Full Text] [Related]
13. Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma.
Gu JL; Li J; Zhou ZH; Liu JR; Huang BH; Zheng D; Su C
Biochem Biophys Res Commun; 2012 Apr; 420(3):644-50. PubMed ID: 22450313
[TBL] [Abstract][Full Text] [Related]
14. Dissecting bortezomib: development, application, adverse effects and future direction.
Cao B; Li J; Mao X
Curr Pharm Des; 2013; 19(18):3190-200. PubMed ID: 23151134
[TBL] [Abstract][Full Text] [Related]
15. Reduced response of IRE1α/Xbp-1 signaling pathway to bortezomib contributes to drug resistance in multiple myeloma cells.
Xu X; Liu J; Huang B; Chen M; Yuan S; Li X; Li J
Tumori; 2017 May; 103(3):261-267. PubMed ID: 27647225
[TBL] [Abstract][Full Text] [Related]
16. Discovery and development of second-generation proteasome inhibitors.
Kirk CJ
Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543
[TBL] [Abstract][Full Text] [Related]
17. Unfolded protein response.
Cao SS; Kaufman RJ
Curr Biol; 2012 Aug; 22(16):R622-6. PubMed ID: 22917505
[No Abstract] [Full Text] [Related]
18. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
[TBL] [Abstract][Full Text] [Related]
19. ER stress arm XBP1s plays a pivotal role in proteasome inhibition-induced bone formation.
Zhang D; De Veirman K; Fan R; Jian Q; Zhang Y; Lei L; Evans H; Wang Y; Lei L; Wang B; Williamson RA; Chantry A; He P; Li A; De Raeve H; Vanderkerken K; He A; Hu J
Stem Cell Res Ther; 2020 Nov; 11(1):516. PubMed ID: 33256835
[TBL] [Abstract][Full Text] [Related]
20. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
